导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -3.74% | 3166/4773 |
| 近一周 | -2.34% | 1851/5462 |
| 近一月 | -3.49% | 1783/5421 |
| 近一季 | -7.79% | 2535/5209 |
| 近半年 | -9.16% | 3452/4920 |
| 近一年 | -0.45% | 2730/4366 |
| 近两年 | 39.99% | 1896/2954 |
| 近三年 | 20.91% | 1437/2253 |
| 成立以来 | -4.47% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-0.19% 1726/4961 |
8.49% 2587/5312 |
- - |
- - |
| 2025 | 25.43% 1709/4813 |
2.56% 1336/3635 |
4.33% 790/4076 |
15.90% 2760/4524 |
1.14% 1504/4813 |
| 2024 | -0.04% 2095/3463 |
-5.92% 1975/2808 |
-0.72% 825/3014 |
12.91% 2275/3129 |
-5.21% 2539/3463 |
| 2023 | -18.59% 1818/2656 |
-4.89% 2120/2280 |
-5.89% 1554/2385 |
-7.82% 1629/2515 |
-1.33% 308/2655 |
| 2022 | -24.53% 1226/2207 |
-17.16% 1185/1919 |
7.73% 437/2016 |
-10.48% 412/2113 |
-5.53% 1934/2208 |
| 2021 | 16.58% 265/1822 |
-5.54% 932/1255 |
18.69% 172/1330 |
8.48% 157/1466 |
-4.14% 1470/1822 |
| 2020 | 50.59% 166/1250 |
2.21% 136/1028 |
24.72% 164/1067 |
11.02% 488/1164 |
6.41% 759/1184 |
| 2019 | 16.68% 683/1092 |
25.26% 475/739 |
-11.64% 770/788 |
-2.47% 702/850 |
8.09% 354/918 |
| 2018 | -32.86% 541/834 |
- - |
-13.42% 444/631 |
-8.88% 496/660 |
-12.15% 414/682 |
| 2017 | -4.54% 506/714 |
- - |
- - |
- - |
- - |
| 2016 | -7.92% 232/605 |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 南方大数据100A VS. 长安沪深300非周期A(740101) |